Oral Solid Dosage CDMO Market To Reach $63.50 Billion By 2030

May 2025 | Report Format: Electronic (PDF)

Oral Solid Dosage CDMO Market Growth & Trends

The global oral solid dosage CDMO market size is expected to reach USD 63.50 billion by 2030, and grow at a CAGR of 6.49% from 2025 to 2030. The increasing demand for outsourcing oral solid dosage manufacturing among pharmaceutical and biopharmaceutical companies has compelled contract development and manufacturing organizations (CDMO) to expand their manufacturing facilities to support the demand of pharmaceutical companies. These expansions are made across the globe to enhance their oral solid dosage industry penetration. Furthermore, the rising demand for generic drugs is a key factor for the market growth as there are increasing numbers of generics as OSD products.

The growing number of patients suffering from chronic and infectious diseases is key factor driving demand for novel therapeutics, thereby positively influencing overall industry progression. In addition, Booming geriatric population that are highly prone to chronic diseases and high adoption rate of OSD among this population further supporting the demand for OSD. Furthermore, another factor contributing to the market growth is adverse drug reactions to existing drugs, which have increased the demand for novel treatment options.

Ongoing technological advancements in the oral solid dosage CDMO market to enhance manufacturing efficiency, product quality, and regulatory compliance are positively influencing overall market growth potential. Continuous manufacturing assists seamless integration of numerous unit operations leading to streamlined production workflows and increased flexibility in manufacturing oral solid dosage forms. Moreover, innovations in techniques such as chromatography, spectroscopy, mass spectrometry, and dissolution testing enabled CDMOs to meet enhanced precision, sensitivity, & reliability in pharmaceutical analysis. Furthermore, the integration of automation, robotics, & data analytics streamlined analytical workflows, reduced turnaround times, and enhanced data integrity & compliance with regulatory standards such as Good Manufacturing Practices (GMP) & International Council for Harmonization (ICH) guidelines.

key Request a free sample copy or view report summary: Oral Solid Dosage CDMO Market Report

Oral Solid Dosage CDMO Market Report Highlights

Basd on product, the tablets segment dominated the market in 2024. The high segment growth is driven by increasing investment in research and development activities, technological advancements in manufacturing processes, innovative drug delivery options and the growing need for advanced solutions to cater to high market demand.
Based on the mechanism, controlled release segment held the largest market share in 2024 attributing to an improved patient compliance, enhanced efficacy & safety, and reduced frequency of administration.
Based on the drug potency, low potent drugs segment held the largest market share in 2024 owing to ease of development and manufacturing processes, high demand for generic drugs coupled with need for cost effective solutions, high patient population and high penetration among multiple therapeutic areas to cater effective patient outcome.
Based on end use, medium & small-size companies segment held the majority revenue share, accounting for over 72.34% in 2024. Growth in the segment can be attributed to the increasing number of small- & medium-sized companies outsourcing their production work to CDMOs and CMOs. Medium and small-sized pharmaceutical companies have limited resources and capabilities in formulation development, process optimization, and manufacturing of oral solid dosage forms. Thus, growing customer preference towards CDMOs for the development and manufacturing of oral solid dosage.
Asia Pacific dominated the oral solid dosage CDMO market with a share of 36.76% in 2024. The outsourcing of pharmaceutical manufacturing to Asian countries, including India and China, has increased due to their lower costs and availability of potential study subjects. This has led to an increase in clinical studies conducted by pharmaceutical companies in the region. Moreover, high availability of raw materials and advanced manufacturing infrastructure will propel regional market growth.

Oral Solid Dosage CDMO Market Segmentation

Grand View Research has segmented the global oral solid dosage CDMO market based on product, mechanism, drug potency, end use, and region:

Oral Solid Dosage CDMO Product Outlook (Revenue, USD Million, 2018 - 2030)

Tablets
- Compressed Tablets
- Orally Disintegrating Tablets (ODT)
- Chewable Tablets
- Bi-layer or Tri-layer Tablets
- Sublingual or Buccal Tablets
- Others
Capsules
- Hard Gelatin Capsules
- Soft Gelatin Capsules
Powders
Granules
Others